Murilo Freitas – Page 35

Ventilator Correction: Philips Updates Use Instructions for Trilogy Evo, EvoO2, EV300, Evo Universal, Aeris EVO, Garbin Evo, and LifeVent EVO2 due to Risk of Inaccurate Flow Measurements Caused By Certain In-Line Nebulizer Placements

Murilo Freitas - 05:00, 18 de November de 2024272

Inline nebulizers in certain configutations on Trilogy Evo continuous ventilators may lead to inaccurate flow measurements which may cause patient injury.

http://www.fda.gov/medical-devices/medical-device-recalls/ventilator-correction-philips-updates-use-instructions-trilogy-evo-evoo2-ev300-evo-universal-aeris

rss

Battery Pack Correction: Smiths Medical Updates Use Instructions for CADD-Solis Li-ion Rechargeable Battery Packs Due to Risk That Pack Damage May Cause a Circuit Short and Prevent Recharge

Murilo Freitas - 05:00, 18 de November de 2024287

Battery casing damage on CADD-Solis battery packs, which provide alternate power to infusion pumps, may cause a circuit short and prevent recharging.

http://www.fda.gov/medical-devices/medical-device-recalls/battery-pack-correction-smiths-medical-updates-use-instructions-cadd-solis-li-ion-rechargeable

rss

FDA Roundup: November 15, 2024

Murilo Freitas - 20:25, 14 de November de 2024283

FDA Roundup: November 15, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-15-2024

rss

Endoscopic Vessel Harvesting System Recall: Getinge and Maquet Cardiovascular Remove VasoView HemoPro 1 and 1.5 Endoscopic Vessel

Murilo Freitas - 05:00, 14 de November de 2024298

HemoPro EVH Systems are being recalled due to a risk for silicone to detach from the device and enter the patient during minimally invasive surgery.

http://www.fda.gov/medical-devices/medical-device-recalls/endoscopic-vessel-harvesting-system-recall-getinge-and-maquet-cardiovascular-remove-vasoview-hemopro

rss

FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

Murilo Freitas - 13:49, 13 de November de 2024240

FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-aromatic-l-amino-acid-decarboxylase-deficiency

rss

FDA Roundup: November 8, 2024

Murilo Freitas - 20:05, 7 de November de 2024298

FDA Roundup: November 8, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-8-2024

rss

FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review

Murilo Freitas - 14:26, 6 de November de 2024468

FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review
http://www.fda.gov/news-events/press-announcements/fda-proposes-ending-use-oral-phenylephrine-otc-monograph-nasal-decongestant-active-ingredient-after

rss

VitalityVita Issues Voluntary Nationwide Recall of VitalityXtra and PeakMax Capsules Due to the Presence of Undeclared Sildenafil and Diclofenac

Murilo Freitas - 05:00, 5 de November de 2024373

Sacramento, CA, VitalityVita.com is voluntarily recalling lot 230811, Exp 8/11/25, of VitalityXtra Capsules and PeakMax Capsules packaged in 10-count blisters in a cardboard carton to the consumer level. VitalityXtra was found to be tainted with sildenafil, an ingredient in FDA approved products for

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitalityvita-issues-voluntary-nationwide-recall-vitalityxtra-and-peakmax-capsules-due-presence

rss

FDA Roundup: November 5, 2024

Murilo Freitas - 22:29, 4 de November de 2024289

FDA Roundup: November 5, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-5-2024

rss

Boulla LLC Issues Voluntary Nationwide Recall of ZoomMax and ZapMax Capsules Due to the Presence of Undeclared Sildenafil and Diclofenac

Murilo Freitas - 05:00, 4 de November de 2024445

Sacramento, CA, Boulla LLC is voluntarily recalling lot YZM240406, Exp 04/05/27, of ZoomMax Capsules and ZapMax Casules packaged in 10-count blisters in a cardboard carton to the consumer level. The products were found to be tainted with sildenafil via testing by the FDA, an ingredient in FDA appro

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/boulla-llc-issues-voluntary-nationwide-recall-zoommax-and-zapmax-capsules-due-presence-undeclared